Pioglitazone, a thiazolidinedione drug, controls the blood sugar level in type-2 diabetic patients. Pioglitazone is used as a single or combination therapy with metformin and has provided better outcomes when adopted with diet and exercise in type-2 diabetic patients. However, despite the health benefits, pioglitazone’s long-term use is associated with weight gain, respiratory tract infections, bone fractures, numbness, and blurred vision. Due to these adverse effects, physicians have shifted their focus from pioglitazone to other effective and safe alternatives. To shed more light on pioglitazone’s clinical utility, Docplexus has organized an exclusive Indian Diabetes League Session on the topic Goodbye to Pioglitazone: Yes / No on 18th May 2021 from 3 PM.
Stay tuned to get more insights! Expert panelists: Yes: Dr. Pradip Raychaudhuri Dr. Rana Bhattacharya Dr. Soumik Goswami Dr.…
